PubAg

Main content area

The effect of camelina sativa oil and fish intakes on fatty acid compositions of blood lipid fractions

Author:
Manninen, S., Lankinen, M., de Mello, V., Ågren, J., Laaksonen, D., Schwab, U., Erkkilä, A.
Source:
Nutrition, metabolism, and cardiovascular diseases 2019 v.29 no.1 pp. 51-61
ISSN:
0939-4753
Subject:
Camelina sativa, alpha-linolenic acid, biomarkers, blood lipids, cardiovascular diseases, cholesteryl esters, erythrocyte membrane, fat intake, fatty fish, food intake, gas chromatography, glucose, lean fish, metabolism, oils, omega-3 fatty acids, phospholipids, triacylglycerols
Abstract:
Blood lipid fractions serve as objective biomarkers of dietary fat intake. It is unclear which fatty acid pool most accurately reflects the dietary intakes of different n-3 PUFAs. We aimed to investigate the effect of fish and camelina sativa oil (CSO) intakes on fatty acid composition of erythrocyte membranes (EM), plasma phospholipids (PL), cholesteryl esters (CE) and triglycerides (TG). We also aimed to identify the most appropriate blood lipid fraction for assessing n-3 PUFA intake.Altogether 79 volunteers with impaired glucose metabolism were randomly assigned either to CSO, fatty fish, lean fish or control groups for 12 weeks. Fatty acid compositions of lipid pools were measured by gas chromatography. The proportion of alpha-linolenic acid (ALA) increased in all lipid pools in the CSO group (false discovery rate (FDR) p < 0.001 for all). Similarly, the proportions of EPA and DHA increased in all lipid fractions in the fatty fish group (FDR p < 0.001 for EM, PL and CE; FDR p = 0.005 for TG; FDR p < 0.001 for EM, PL, CE; FDR p < 0.007 for TG, respectively). Changes in the dietary intakes of ALA, EPA and DHA correlated with the changes in their proportions in all lipid pools (r = 0.3–0.5, p < 0.05).There is no difference in the ability of blood lipid fractions in reflecting the dietary intake of different n-3 PUFAs over a time period of 12 weeks in subjects with high baseline omega-3 index.This trial was registered in Clinicaltrials.gov (NCT01768429)
Agid:
6180178